Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Moodys
McKesson
AstraZeneca
Express Scripts

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MIPOMERSEN SODIUM

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Mipomersen Sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00362180 Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration Completed Ionis Pharmaceuticals, Inc. Phase 2 2006-07-01 This study will assess what, if any, effect that ISIS 301012 (mipomersen) has on liver triglyceride content in multiple groups of subjects with varying degrees of risk for hepatic steatosis. In order to enroll subject groups with varying degrees of risk, the study has included multiple cohorts (Cohorts A-G). Additions and removal of cohorts has been accomplished with protocol amendments.
NCT00362180 Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration Completed Kastle Therapeutics, LLC Phase 2 2006-07-01 This study will assess what, if any, effect that ISIS 301012 (mipomersen) has on liver triglyceride content in multiple groups of subjects with varying degrees of risk for hepatic steatosis. In order to enroll subject groups with varying degrees of risk, the study has included multiple cohorts (Cohorts A-G). Additions and removal of cohorts has been accomplished with protocol amendments.
NCT00477594 Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia Completed Ionis Pharmaceuticals, Inc. Phase 2 2007-05-01 The purpose of this study is to evaluate the safety and efficacy of extended dosing of mipomersen in patients with familial hypercholesterolemia on lipid-lowering therapy who have completed either the 301012-CS8 (NCT00280995) or 301012-CS9 (NCT00281008) clinical drug trials.
NCT00477594 Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia Completed Kastle Therapeutics, LLC Phase 2 2007-05-01 The purpose of this study is to evaluate the safety and efficacy of extended dosing of mipomersen in patients with familial hypercholesterolemia on lipid-lowering therapy who have completed either the 301012-CS8 (NCT00280995) or 301012-CS9 (NCT00281008) clinical drug trials.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Mipomersen Sodium

Condition Name

Condition Name for Mipomersen Sodium
Intervention Trials
Hypercholesterolemia 7
Metabolic Disorder 5
Metabolic Diseases 5
Lipid Metabolism Disorders 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Mipomersen Sodium
Intervention Trials
Hypercholesterolemia 8
Lipid Metabolism Disorders 5
Dyslipidemias 5
Disease 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Mipomersen Sodium

Trials by Country

Trials by Country for Mipomersen Sodium
Location Trials
United States 73
Canada 12
United Kingdom 4
South Africa 3
Taiwan 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Mipomersen Sodium
Location Trials
Ohio 6
Missouri 4
Massachusetts 4
Florida 4
North Carolina 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Mipomersen Sodium

Clinical Trial Phase

Clinical Trial Phase for Mipomersen Sodium
Clinical Trial Phase Trials
Phase 3 5
Phase 2 3
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Mipomersen Sodium
Clinical Trial Phase Trials
Completed 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Mipomersen Sodium

Sponsor Name

Sponsor Name for Mipomersen Sodium
Sponsor Trials
Kastle Therapeutics, LLC 9
Ionis Pharmaceuticals, Inc. 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Mipomersen Sodium
Sponsor Trials
Industry 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Harvard Business School
McKinsey
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.